Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

NCT05401357 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-Angle
Ocular Hypertension

Interventions

DRUG: Test - Bimatoprost 0.01% Ophthalmic Solution
DRUG: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

Sponsor

Amneal Pharmaceuticals, LLC

Collaborators

[object Object]